0 avis
Sécurité et efficacité de la phacoémulsification combinée à l'implantation de iStent Inject dans le glaucome chronique à angle ouvert associé à une cataracte
Archive ouverte
Edité par CCSD ; Elsevier Masson -
International audience. Background: The goal of this study was to assess the efficacy and safety of phacoemulsification combined with iStent Inject® implantation for the treatment of chronic open-angle glaucoma controlled on topical anti-glaucoma medications and associated with cataract. Methods: This study was a retrospective analysis of patients who underwent phacoemulsification and implantation of an iStent Inject® for chronic open-angle glaucoma associated with cataract. For all patients, pre- and postoperative characteristics, including number of glaucoma medications and intraocular pressure (IOP), were compared using Paired-sample t-tests and Wilcoxon signed-rank tests, respectively. Postoperative visits were scheduled at 7 days and 1, 3, 6, and 12 months after surgery. Results: Forty-nine eyes of 39 patients were included in the study. Mean preoperative IOP at baseline was 16.3 ± 4.3 mmHg (range, 10-29 mmHg) with a mean of 2.2 ± 1.0 mmHg antiglaucoma medications. At 1 month, the mean IOP reduction was 16% (P < 0.05) along with an 18.7% reduction in the mean number of medications. At 6 months, the mean IOP was 12.8 ± 2.6, with a mean of 1.1 ± 0.9 antiglaucoma medications. The mean IOP reduction at 6 months was 22% (P < 0.05) along with a 49% reduction in the mean number of medications. At 12 months, the mean IOP was 13.8 ± 2.5 with a mean of 1.1 ± 1.2 medications. The mean IOP reduction at 12 months was 15% (P < 0.05) along with a 47% reduction in the mean number of medications. No severe device-related side effects were observed. Conclusions: iStent Inject® implantation combined with phacoemulsification resulted in effective IOP reduction and medication burden in patients with mild to advanced chronic open-angle glaucoma and preoperative IOP well controlled with topical hypotensive medications.